ALS Better Care Act
- Bill Number
- S. 3763
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 2
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2026-02-03: Read twice and referred to the Committee on Finance.
- Last Updated
- 2026-03-31T23:15:45Z
AI-Generated Summary
Purpose of the Legislation
The ALS Better Care Act (S. 3763) aims to improve Medicare coverage for people diagnosed with amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, leading to muscle weakness and loss of function. It seeks to address gaps in care by reimbursing specialized services that help manage ALS symptoms, extend lifespans, and enhance quality of life, while also tackling issues like inadequate funding for clinical trials.
Key Provisions
- Short Title and Findings: The bill is titled the "ALS Better Care Act." It includes congressional findings highlighting ALS as a debilitating disease, the critical role of multidisciplinary services (e.g., therapy, respiratory support, and equipment coordination), the benefits of specialized ALS clinics, reimbursement shortfalls under current Medicare rules, the need for telehealth in rural or underserved areas, and challenges in funding and staffing ALS clinical trials.
- Medicare Coverage for ALS-Related Services (Section 3):
- Adds ALS-related services to Medicare Part B (outpatient coverage) starting January 1, 2027.
- Defines "ALS-related services" as a bundle of outpatient care items provided by qualified providers (or their arrangements), including:
- Specialized physician or nurse practitioner support.
- Occupational therapy, speech pathology, and physical therapy.
- Dietary and respiratory support.
- Registered nurse support.
- Coordination for durable medical equipment (e.g., wheelchairs or ventilators needed for ALS management).
- Eligibility: Limited to "covered ALS individuals," defined as those medically diagnosed with ALS (using criteria similar to Social Security disability rules).
- Qualified providers must demonstrate capability to deliver these services and meet Secretary of Health and Human Services (HHS) standards, developed with input from patients, physicians, and ALS organizations.
- Payment System for ALS-Related Services:
- Establishes a single bundled payment per visit to qualified providers, in addition to other Medicare payments.
- Base amounts: $800 in 2027 and 2028 (or higher if recommended by a Comptroller General report); for 2029 onward, adjusted annually by an "ALS services market basket" (a measure of cost increases for these services) or updated recommendations every three years starting in 2030.
- Comptroller General reports (due January 1, 2027, and every third year) will recommend payment levels based on historical utilization data from Medicare, private insurers, or expert estimates, focusing on years with high patient needs.
- Adjustments: Extra payments for providers in clinical trials (to cover added costs) and for new ALS-related technologies or services not previously reimbursed if their costs are significant.
- Claims process: Providers submit claims using ICD-10-CM codes (standard medical diagnosis codes) for ALS.
- No patient cost-sharing (e.g., deductibles or copays) for these services; payments made on an "assignment-related basis" (providers accept Medicare's rate as full payment).
- Report on ALS Clinical Trials (Section 4):
- Requires HHS, through the National Institute of Neurological Disorders and Stroke (NINDS), to submit a report to Congress within 90 days of enactment.
- Report must identify challenges in administering and staffing ALS trials (e.g., low funding delaying treatments), actions NINDS can take, and legislative recommendations (including funding requests) to improve trials.
- Implementation and Conforming Changes:
- HHS can use program instructions for most provisions but must use formal rulemaking (public comment process) for defining qualified providers.
- Ensures these payments do not reduce other Medicare outpatient payments and clarifies that qualified providers can arrange services like other specialized programs.
Significant Changes to Existing Law
- Expansion of Medicare Benefits: Amends the Social Security Act (Sections 1861 and 1834) to create a new, dedicated subcategory for ALS-related services under Medicare Part B, which previously lacked bundled reimbursement for multidisciplinary ALS care. This introduces the first disease-specific bundled payment model for outpatient ALS management.
- New Payment Methodology: Shifts from fragmented reimbursements (e.g., separate billing for each therapy) to a single per-visit payment with inflation adjustments and periodic expert reviews, addressing current "inadequate" rates that discourage specialized clinics.
- Trial Adjustments and Reporting: Adds incentives for clinical trial participation and mandates a targeted HHS report on trial barriers, which is not currently required under existing NIH or Medicare laws.
- Telehealth Support: While not mandating coverage, the findings emphasize telehealth's role, potentially influencing future expansions (Medicare already expanded telehealth post-COVID but with limits for rural care).
Potential Impacts
- On Citizens: ALS patients (about 30,000 in the U.S., with 5,000 new diagnoses yearly) gain better access to comprehensive, coordinated care without copays, potentially extending survival (studies cited show 10+ months added in specialized clinics) and reducing travel burdens, especially in rural areas via telehealth. Families and caregivers benefit from reduced wait times and improved quality of life.
- On Government Agencies: HHS and the Centers for Medicare & Medicaid Services (CMS) must develop and administer the new payment system, including claims processing and provider qualifications, increasing administrative workload but with flexibility via instructions. NIH/NINDS faces requirements for the trials report, possibly leading to new funding needs. Overall, adds costs to Medicare (estimated bundled payments could total millions annually, though offset by better outcomes reducing long-term hospitalizations).
- On International Relations: No direct impacts; the bill is domestic-focused on U.S. Medicare and research.
Main Stakeholders Affected
- ALS Patients and Families: Primary beneficiaries, gaining enhanced care access and financial relief.
- Healthcare Providers: Specialized ALS clinics, multidisciplinary teams (physicians, therapists, nurses), and facilities benefit from better reimbursements, encouraging expansion and innovation; rural providers gain telehealth emphasis.
- Government Entities: HHS, CMS (for payments), NIH/NINDS (for reporting), and Congress (for recommendations and potential appropriations).
- Researchers and Non-Profits: Clinical trial staff and ALS organizations (e.g., ALS Association) influenced by funding/staffing improvements and input on provider rules.
- Insurers: Private plans and Medicare Advantage programs may see indirect effects from Comptroller General data on their payments.
Notable Legal, Constitutional, or Political Implications
- Legal Implications: Establishes a precedent for disease-specific Medicare bundles, potentially streamlining care for other rare diseases (e.g., via similar models) while ensuring compliance with existing anti-fraud rules (e.g., ICD coding). The no-cost-sharing provision aligns with Medicare's structure but could face challenges if costs escalate without caps. Rulemaking for providers promotes transparency and stakeholder involvement, reducing litigation risks.
- Constitutional Implications: None significant; falls under Congress's enumerated powers to tax and spend for general welfare (Medicare amendments are routine and upheld).
- Political Implications: Bipartisan sponsorship (Republican Murkowski and Democrat Coons) signals broad support for rare disease funding amid debates on Medicare sustainability. It balances innovation incentives with cost controls (e.g., market basket adjustments), but could spark discussions on expanding to other conditions or addressing trial funding shortfalls, especially with ALS's high unmet needs and low survival rates (median 2-5 years post-diagnosis).
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (1)
Sen. Coons, Christopher A. [D-DE]
Recent Actions
- 2026-02-03: Read twice and referred to the Committee on Finance.
- 2026-02-03: Introduced in Senate
Bill Versions
- ALS Better Care Act — issued 2026-02-03 — PDF (14 pages)